Academia Discounts Available To University Programs

Auto Parts & Vehicles Lorem ipsum dolor sit amet sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Shop now Never miss a sale Automotive Battery Lorem ipsum dolor sit amet sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Shop now new products Tools & Equipment Lorem ipsum dolor sit amet sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Shop now Tire & Wheel Tools home-6-slide1 home-6-slide2 home-6-slide3

99.9% Purity USA MADE PEPTIDES The Latest Peptides Researched On The Market shop now Academia product pricing UNIVERSITY
RESEARCH
Special Pricing And Bulk Deals For Qualified Universities
Get The NEwsletter Promotional Offers Sign Up For Promotional Offers

Premium Peptides for Scientific Research and Development

Research Peptides™ is a trusted leader in providing top-tier peptides, proteins, and amino acid derivatives crafted exclusively for scientific research and development. Leveraging cutting-edge automated and manual peptide synthesis technologies, including advanced solid-phase and solution-phase methods, we deliver research-grade peptides with exceptional purity levels surpassing 99%. Our meticulous process, from synthesis to secure packaging and swift delivery, adheres to the highest industry standards, ensuring each peptide is optimized for stability and performance in laboratory settings. At our state-of-the-art in-house analytical lab, we conduct rigorous testing at every production stage, using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry to validate the purity, identity, and precision of each peptide’s molecular structure. Choose Research Peptides™ for unparalleled quality and reliability in your research, backed by our commitment to advancing scientific discovery.

Top Research Products

Foxo4-DRI

$295.00

Thymalin

$17.00

Tesamorelin

$50.00$75.00

SNAP-8

$60.00

Semax

$35.00

Selank

$35.00

PT-141

$50.00

NAD+

$75.00

MOTS-c

$55.00

Mazdutide

$100.00

LL-37

$85.00

KPV

$54.00

Ipamorelin

$46.00$155.00

Research Developments

Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State—New Directions in Anti-Aging Regenerative Therapies

Published in Cells on June 15, 2021, this review article explores the potential of developmentally essential secreted peptides, particularly thymosin beta-4 (Tβ4), to induce regenerative and anti-aging effects by reverting adult organs to an embryonic-like state. Authored by Janusz K. Rybak and colleagues, the study delves into the molecular mechanisms of Tβ4, a 43-amino-acid peptide […]

Two-Year Effects of Semaglutide in Adults with Overweight or Obesity: The STEP 5 Trial

Published in Nature Medicine on October 10, 2022, this phase 3, double-blind, randomized, placebo-controlled trial (STEP 5) evaluates the long-term efficacy and safety of once-weekly subcutaneous semaglutide (2.4 mg) in adults with overweight or obesity but without diabetes. The study enrolled 304 participants with a body mass index (BMI) of ≥30 kg/m² or ≥27 kg/m² […]

Once-Weekly Semaglutide in Adults with Overweight or Obesity

Published in The New England Journal of Medicine on February 10, 2021, this study investigates the efficacy and safety of once-weekly subcutaneous semaglutide (2.4 mg) for weight loss in adults with overweight or obesity but without diabetes. Conducted as a double-blind, randomized, placebo-controlled trial, the study enrolled 1,961 participants with a body mass index (BMI) […]

Tirzepatide as Compared with Semaglutide for the Treatment of Obesity

Published in The New England Journal of Medicine on May 11, 2025, this phase 3b, open-label, randomized trial compares the efficacy and safety of tirzepatide (10 or 15 mg once weekly) with semaglutide (1.7 or 2.4 mg once weekly) for weight loss in adults with obesity but without type 2 diabetes. Conducted across 47 sites […]

Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

Published in The New England Journal of Medicine on June 13, 2019, this study evaluates the cardiovascular safety and efficacy of oral semaglutide, the first oral glucagon-like peptide-1 (GLP-1) receptor agonist, in patients with type 2 diabetes at high cardiovascular risk. The PIONEER 6 trial, a double-blind, randomized, placebo-controlled study, enrolled 3,183 participants with type […]

Search for products

Back to Top
Product has been added to your cart